Heron Therapeutics, Inc. (HRTX) vs Xilio Therapeutics, Inc. (XLO)

Heron Therapeutics, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Heron Therapeutics, Inc. and Xilio Therapeutics, Inc. are of similar size ($59.2M and $57.0M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against 0.99%. Heron Therapeutics, Inc. has the higher net margin (−22.5% vs −34.1%) and the lower return on invested capital (−6.35% vs 0.00%). Across the 17 metrics below, Xilio Therapeutics, Inc. leads on 9 and Heron Therapeutics, Inc. on 8.

Valuation

Metric HRTX XLO Biotechnology median
P/E n/m n/m 7.88
P/S 0.38 2.74 11.47
P/B 9.75 2.43 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.04 0.75 10.73
Earnings yield (63.33%) (16.49%) (28.84%)
Free cash flow yield (21.17%) (34.93%) (23.03%)

Profitability

Metric HRTX XLO Biotechnology median
Gross margin 70.07% 100.00% 65.16%
Operating margin (7.19%) (48.94%) 0.00%
Net margin (22.52%) (34.06%) 0.00%
Free cash flow margin (8.00%) (95.59%) 0.00%
Return on equity 318.21% (55.03%) (57.72%)
Return on assets (14.06%) (15.16%) (49.22%)
Return on invested capital (6.35%) 0.00% 0.00%

Growth

Metric HRTX XLO Biotechnology median
Revenue growth (TTM) 0.99% 327.25% 5.64%
EPS growth (last fiscal year) (33.33%) 72.55% —
Revenue growth, 5-year CAGR 11.81% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HRTX XLO Biotechnology median
Debt to equity 20.65 0.00 0.00
Current ratio 2.49 4.25 4.73
Net debt to EBITDA (643.88) 3.40 0.96

Dividend

Metric HRTX XLO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HRTX XLO Biotechnology median
Market cap 56.96m 59.22m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack